Title |
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
|
---|---|
Published in |
Trials, June 2009
|
DOI | 10.1186/1745-6215-10-39 |
Pubmed ID | |
Authors |
Matthew R Sydes, Mahesh KB Parmar, Nicholas D James, Noel W Clarke, David P Dearnaley, Malcolm D Mason, Rachel C Morgan, Karen Sanders, Patrick Royston |
Abstract |
The multi-arm multi-stage (MAMS) trial is a new paradigm for conducting randomised controlled trials that allows the simultaneous assessment of a number of research treatments against a single control arm. MAMS trials provide earlier answers and are potentially more cost-effective than a series of traditionally designed trials. Prostate cancer is the most common tumour in men and there is a need to improve outcomes for men with hormone-sensitive, advanced disease as quickly as possible. The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 8 | 29% |
United Kingdom | 6 | 21% |
India | 1 | 4% |
Ireland | 1 | 4% |
Singapore | 1 | 4% |
Canada | 1 | 4% |
Unknown | 10 | 36% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 13 | 46% |
Practitioners (doctors, other healthcare professionals) | 8 | 29% |
Scientists | 6 | 21% |
Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
China | 1 | <1% |
Vietnam | 1 | <1% |
Unknown | 152 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 39 | 25% |
Student > Master | 19 | 12% |
Student > Ph. D. Student | 18 | 12% |
Other | 11 | 7% |
Professor | 10 | 6% |
Other | 29 | 19% |
Unknown | 30 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 63 | 40% |
Mathematics | 10 | 6% |
Psychology | 6 | 4% |
Biochemistry, Genetics and Molecular Biology | 5 | 3% |
Nursing and Health Professions | 4 | 3% |
Other | 23 | 15% |
Unknown | 45 | 29% |